MedTrace Logo

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

NCT01005199 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2019-05-15

No results posted yet for this study

Summary

RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This randomized phase II trial is studying giving sorafenib tosylate together with everolimus to see how well it works compared with sorafenib tosylate alone in treating patients with localized, unresectable, or metastatic liver cancer.

Conditions

Interventions

DRUG

everolimus

Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily

DRUG

sorafenib tosylate

Sorafenib 2 x 400 mg daily

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Dieter Koeberle, MD · Cantonal Hospital of St. Gallen

  • Jean-Francois Dufour, MD · Insel Gruppe AG, University Hospital Bern

  • Gyorgy Bodoky, MD, PhD · Szent Laszlo Korhaz

  • Michael Montemurro, MD · CHUV Lausanne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2013-06-30
Completion
2016-03-31

Countries

  • Austria
  • Hungary
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01005199 on ClinicalTrials.gov